The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous ...

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with p ...

JACK MAYE didn’t want to tell anybody. In his freshman year, when he took off his Bedford High School football helmet and flakes fell out, Maye’s teammates would tell him that he had some bad dandruff ...

JACK MAYE didn’t want to tell anybody. In his freshman year, when he took off his Bedford High School football helmet and flakes fell out, Maye’s teammates would tell him that he had some bad dandruff ...

In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL ... STEQEYMA full interchangeability with ...

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...